The New Yorker: “Ganodermaceae” is the New Yorker’s first ever new cannabis strain

New Yorker editors and staff are finally starting to feel comfortable in the cannabis plant.

The New York Times, The Washington Post, The Atlantic, and others have all published articles about the new strain.

But the New York Post, which first published the article, did not use cannabis as the primary theme.

This is because the newspaper was founded by cannabis advocate Richard Nixon, and cannabis was the primary focus of Nixon’s administration.

The paper did not choose to use cannabis in the article.

Rather, it used its own cannabis strain as a focus.

The article by the New Republic’s Adam Gopnik, however, was a big hit.

The NYT used cannabis as a central theme and the Washington Post and Atlantic used it as a secondary theme.

However, cannabis was not even mentioned as a main theme in either article.

The Times also chose not to use the term “cannabis,” although it was written about the plant and its use in a way that included the word.

The Atlantic used cannabis and said it was “one of the most powerful medicines of all time.”

The New Republic did not.

In a piece about the strain, the Times’ medical editor said it “does not smell as much as a weed and tastes like an after-dinner cigar.”

The article did not mention cannabis in its title either.

Instead, the article described the strain as “a new breed of weed” and described it as having “a low acid content that’s more potent than that of most other marijuana strains.”

The Times’ cannabis editor, Dr. David Finkelstein, called the NYT’s cannabis strain a “new breed of cannabis.”

He said, “it’s a hybrid of marijuana and marijuana-infused coffee.

And it’s so different, it’s a totally different strain than most of the strains that you find in the medical marijuana market.”

The Washington Times’ marijuana editor, James Pethokoukis, called cannabis “the most potent medicinal cannabis” and said “it can relieve a lot of the symptoms of arthritis, and some of the side effects of cancer.”

The Atlantic’s cannabis editor wrote that it “is a potent strain of cannabis, and I don’t know of any other strain of marijuana that’s as potent as it is.”

And the New England Journal of Medicine’s cannabis medical editor, Stephen Guttentag, wrote that the strain was “a powerful, potent medicine that can help with chronic pain, nausea, and seizures.”

Guttenteak added that it is “not going to get you high.”

And Pethokinas, a New York-based cannabis activist, said that “it does not smell, tastes, and smells like marijuana.”

In his piece, Finkelis called cannabis a “vastly different strain of pot than any other.”

The NYT’s marijuana editor added that the NYT is “a marijuana critic and an activist and a cannabis advocate,” adding that he was “proud” of its cannabis strain.

The NY Times’ Marijuana editor, Elizabeth Weise, called it a “bizarre and bizarre strain of plant” and the Atlantic’s marijuana reporter, Dan Schrag, said it is a “mixture of different strains of cannabis that all come together in this amazing, potent mixture.”

Gopik, the NYT marijuana editor and a longtime cannabis activist who has worked on cannabis issues at the paper, said the NYT Cannabis strains were “totally different than any strain you’re going to find in other strains.”

He added, “the strain itself is totally different than most strains.”

According to the NYT article, the strain has a THC level of more than 30 percent.

But, according to the article by The New Journal of Cannabis, the THC level is closer to 20 percent, and its CBD levels are “only” about 10 percent.

“The difference between THC and CBD is about the same, so if you are looking for a high, you’re looking for THC,” Gopiyak said.

Guttency, a cannabis activist at the Times, said he is not sure why the NYT cannabis strain is not mentioned as the main focus of the article and the NYT did not make any reference to cannabis in any of the articles about it.

“I’m just not sure how we should treat it,” he said.

But Finkelsteins and Guttens said they do not think the NYT should have been upfront about cannabis in an article about a strain they consider the best cannabis strain available.

Goplin said that the New Times’ Cannabis article was “too far out of line” for the Times to be referring to cannabis as “the best strain available.”

“If the NYT wanted to be honest about cannabis, they could have called it CBD, or THC-infusion coffee,” he added.

Finkelsen said he thinks the NYT needs to be more honest with its cannabis strains because “the fact is,